Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
about
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderA new look at an old drug: neuroprotective effects and therapeutic potentials of lithium saltsDysregulation and restoration of translational homeostasis in fragile X syndromeThe pathophysiology of fragile X (and what it teaches us about synapses)Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesWnt signaling networks in autism spectrum disorder and intellectual disabilityDelineating the Common Biological Pathways Perturbed by ASD's Genetic Etiology: Lessons from Network-Based StudiesA review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndromeImpairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3.Loss of neuronal GSK3β reduces dendritic spine stability and attenuates excitatory synaptic transmission via β-cateninGSK3β inhibition promotes synaptogenesis in Drosophila and mammalian neurons.New X-chromosomal interactors of dFMRP regulate axonal and synaptic morphology of brain neurons in Drosophila melanogasterGSK3β isoform-selective regulation of depression, memory and hippocampal cell proliferation.Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Lithium to the Rescue.Characterization of maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitors as stimulators of steroidogenesis.Translation: screening for novel therapeutics with disease-relevant cell types derived from human stem cell models.Fragile X mental retardation protein regulates trans-synaptic signaling in DrosophilaGlycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice.What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders.Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.Development of mavoglurant and its potential for the treatment of fragile X syndrome.Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseasesLISPRO mitigates β-amyloid and associated pathologies in Alzheimer's mice.Developing BACE-1 inhibitors for FXS.Differentiation from human pluripotent stem cells of cortical neurons of the superficial layers amenable to psychiatric disease modeling and high-throughput drug screeningNeurological functions of the masterswitch protein kinase - gsk-3.Fragile X Mental Retardation Protein Regulates Activity-Dependent Membrane Trafficking and Trans-Synaptic Signaling Mediating Synaptic Remodeling.Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome.
P2860
Q24626017-7579009C-0728-4AA7-9A9A-75147BF92977Q26741164-0E365E82-6D32-4214-8C70-0B0B02FF94F9Q26782616-F5240638-578F-440A-9C42-5C650676249DQ27010675-477CE9B1-36D4-41E8-AD75-FCBCE887242FQ27023257-5CFF6FC1-F2F6-455F-BED7-61DC05AD45A3Q28074740-37602EA4-D2C1-4105-8819-658EDA320669Q33624758-9B0F2DD0-06A3-4556-B55E-7ADD4B056DEDQ34392818-0986B9AE-CB8D-4521-B369-8ABB01508239Q34869830-832FEFAC-9C8C-475C-8667-A2698FF69896Q35146005-AC4F1F38-7D5F-49F2-8772-3C95453D01D3Q35228923-1FEFBEBB-CEA3-4321-9015-7F20EF98E840Q35575758-B865067A-98A1-4E68-8125-68556D6852D5Q36384227-E230D847-54F0-4E53-B654-91B38DD6117BQ36649760-8228FA8B-BE81-458A-9DA7-00175D3969BFQ37054398-A61DCDBD-81FB-4374-AC1A-B8F3913B0231Q37078843-0632999B-C737-450A-968C-B1E6A1D4F504Q37184659-AB67C0EE-7F86-499E-BE3B-87B8480A99C1Q37275071-13146455-F053-47E8-9459-84747610EF63Q37287441-B267DF32-915E-4E0C-81D7-396267489D3FQ37417156-F6E6E566-6398-4840-99F1-07020F0180B2Q37711788-E6568FF8-7D35-479A-9951-2D5BC194DDD3Q38038399-F3C7F734-899D-49BC-93C2-9F289B889016Q38126701-6EBA276C-0090-45C1-8B0A-853C05D06792Q38164021-C546898A-85D2-4A73-90D9-A507B55DA173Q38266162-70226156-1422-40B7-8A57-88FCDDD965DDQ38272835-4D128496-5460-46B8-B53E-5F962A0B6120Q38724561-4B15A78F-1A38-4EED-8424-89C574EAA955Q41073215-D6B37199-34C5-495A-93CE-C2966D680B06Q41765005-3ABB43F6-1465-483C-AEEE-3C3704BF5EC3Q42195030-851C554A-CE88-4114-A7A2-AC9A758A83B0Q47551369-C0B5FE07-8F80-4A7B-BAD2-9796727E3E79Q47903798-2AF4333F-43BC-476C-87BC-57A0318E1C52
P2860
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
@ast
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
@en
type
label
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
@ast
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
@en
prefLabel
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
@ast
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
@en
P2860
P356
P1476
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
@en
P2093
Marjelo A Mines
Richard S Jope
P2860
P356
10.3389/FNMOL.2011.00035
P577
2011-11-01T00:00:00Z